Basilea Pharmaceutica Ltd. has entered into an asset purchase agreement with Spexis AG for a preclinical program of antibiotics from a novel class, targeting gram-negative bacteria, including multidrug-resistant strains.
Researchers from Yangzhou University presented the discovery and preclinical characterization of LysZX4-NCA, a new endolysin therapeutic being developed for the treatment of multidrug-resistant highly virulent Klebsiella pneumoniae (MDR-hvKP) infections.
Benzamide compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors have been reported in an F. Hoffmann-La Roche Ltd. patent to be useful for the treatment of gram-negative bacterial infections, particularly Klebsiella pneumoniae and Escherichia coli infections.
Phaxiam Therapeutics SA has initiated a new preclinical development program targeting Klebsiella pneumoniae, which is responsible for severe infections and notable for its high resistance to antibiotics.
Tuojie Biotech (Shanghai) Co. Ltd. has disclosed boric acid derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infections.
A Taiwanese study has demonstrated that human placental mesenchymal stem cells were therapeutic in hypervirulent Klebsiella pneumonia intra-abdominal infections by secreting IL-1beta to augment neutrophil numbers and functions, while restraining immune responses by other leukocytes.
